A look into Akero Therapeutics Inc. (AKRO)’s deeper side

Akero Therapeutics Inc. (NASDAQ: AKRO) stock fell -2.89% on Tuesday to $44.34 against a previous-day closing price of $45.66. With 0.95 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.66 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $48.14 whereas the lowest price it dropped to was $43.34. The 52-week range on AKRO shows that it touched its highest point at $54.88 and its lowest point at $7.52 during that stretch. It currently has a 1-year price target of $59.14. Beta for the stock currently stands at -0.93.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AKRO was down-trending over the past week, with a drop of -4.44%, but this was down by -1.38% over a month. Three-month performance dropped to -0.96% while six-month performance rose 0.36%. The stock gained 394.31% in the past year, while it has lost -19.09% so far this year. A look at the trailing 12-month EPS for AKRO yields -2.74 with Next year EPS estimates of -3.48. For the next quarter, that number is -0.62. This implies an EPS growth rate of 0.70% for this year and -14.90% for next year.

Float and Shares Shorts:

At present, 46.94 million AKRO shares are outstanding with a float of 35.46 million shares on hand for trading. On Apr 27, 2023, short shares totaled 4.65 million, which was 9.89% higher than short shares on Mar 30, 2023. In addition to Dr. Andrew Cheng M.D., Ph.D. as the firm’s Pres, CEO & Director, Dr. Jonathan M. Young J.D., Ph.D. serves as its Co-Founder, Exec. VP, COO & Sec.

Institutional Ownership:

Through their ownership of 108.40% of AKRO’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 64.15% of AKRO, in contrast to 34.10% held by mutual funds. Shares owned by individuals account for 30.94%. As the largest shareholder in AKRO with 8.14% of the stake, Avidity Partners Management LP holds 3,825,000 shares worth 3,825,000. A second-largest stockholder of AKRO, Janus Henderson Investors US LLC, holds 3,334,661 shares, controlling over 7.10% of the firm’s shares. Alkeon Capital Management LLC is the third largest shareholder in AKRO, holding 3,243,915 shares or 6.91% stake. With a 3.30% stake in AKRO, the ACAP Strategic Fund is the largest stakeholder. A total of 1,549,936 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 3.02% of AKRO stock, is the second-largest Mutual Fund holder. It holds 1,416,959 shares valued at 63.39 million. Vanguard Total Stock Market ETF holds 2.76% of the stake in AKRO, owning 1,294,656 shares worth 57.92 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, AKRO reported revenue of $0.00 and operating income of -$27.59M. The EBITDA in the recently reported quarter was -$27.34M and diluted EPS was -$0.77.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AKRO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With AKRO analysts setting a high price target of $70.00 and a low target of $48.00, the average target price over the next 12 months is $59.14. Based on these targets, AKRO could surge 57.87% to reach the target high and rise by 8.25% to reach the target low. Reaching the average price target will result in a growth of 33.38% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded AKRO stock several times over the past three months with 4 Buys and 12 Sells. In these transactions, 115,000 shares were bought while 79,285 shares were sold. The number of buy transactions has increased to 36 while that of sell transactions has risen to 85 over the past year. The total number of shares bought during that period was 563,032 while 2,531,299 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *